Morphosys CEO says MOR202 drug candidate still promising: newspaper

Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper. "We are still testing the MOR202 compound in the first clinical phase and still see it as promising," German weekly Welt am Sonntag quoted Simon Moroney as saying in an interview published on Sunday. Morphosys and Celgene agreed last month to end their cooperation on MOR202, pushing Morphosys' stock down more than 20 percent.



via Health News Headlines - Yahoo News http://ift.tt/19TjI9i